This product consists of a CRISPR/Cas9-edited polyclonal cell population in which the ARPIN gene has been disrupted in SK-HEP-1 human hepatic adenocarcinoma cells, providing a loss-of-function model for investigating actin cytoskeleton dynamics and cell motility. The polyclonal knockout pool is generated by Cas9-mediated targeting, yielding a heterogeneous mixture of cells with gene disruption events, and is not a clonally derived line. It offers a versatile tool for studies where gene ablation at the population level is sufficient to observe phenotypic changes, allowing researchers to assess the functional consequences of ARPIN deficiency without the selection bottlenecks associated with single-cell cloning.
The parental SK-HEP-1 cell line was established from the ascitic fluid of a 56-year-old male patient diagnosed with liver adenocarcinoma. This line is notable for its dual epithelial and endothelial features, expressing markers such as von Willebrand factor and CD31, which render it useful as an endothelial surrogate model for angiogenesis and vascular biology research. SK-HEP-1 cells are highly tumorigenic in nude mice and retain features of hepatocellular carcinoma progression, making them a relevant host for studying liver cancer metastasis and the tumor microenvironment.
ARPIN (Arp2/3 inhibitor protein) functions as a key negative regulator of the Arp2/3 complex, directly binding to the complex and sterically blocking its activation by nucleation-promoting factors WAVE2 and N-WASP. This inhibition reduces branched actin polymerization at the leading edge of cells, thereby suppressing the formation of lamellipodia and filopodia and attenuating cell migration and invasion. Upstream signals include integrin-mediated adhesion and miR-31, while downstream consequences involve reorganization of F-actin networks and focal adhesion turnover. ARPIN operates within the Rho GTPase signaling axis, where Rac1 and Cdc42 govern WAVE2 and N-WASP activity upstream, and ARPIN acts as a molecular brake on Arp2/3-mediated actin nucleation.
In the SK-HEP-1 context, loss of ARPIN is expected to derepress Arp2/3 activity, leading to enhanced branched actin assembly and potentially increased migratory and invasive capacity. Given the cell line’s hepatic origin and endothelial-like properties, this model is particularly suited for dissecting the molecular mechanisms that drive hepatocellular carcinoma dissemination and tumor angiogenesis. It enables the study of how ARPIN??s antimigratory function intersects with the liver cancer epithelial?Cmesenchymal transition and with the angiogenic switch in endothelial-like cells, offering a platform to probe metastasis and neovascularization pathways.
This knockout cell population is applicable to a range of experimental workflows, including wound healing migration assays and transwell invasion assays to quantify motility changes, phalloidin staining for F-actin visualization by fluorescence microscopy, western blotting to confirm ARPIN loss and monitor Arp2/3 subunit levels, co-immunoprecipitation to probe protein?Cprotein interactions within the Arp2/3 complex, and Rho GTPase activity assays to connect signaling to cytoskeletal outputs. It supports drug screening for anti-metastatic compounds and investigation of Rho GTPase-dependent pathways. For additional technical details or to order this product, please contact Ascent Research.
